Home > Insider Trading > Filing (0000899243-18-027475)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1664106	Logicbio Therapeutics Inc.	LOGC	Biological Products, (No Disgnostic Substances) (2836)	471514975

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1706399	Erez Chimovits	C/O Logicbio Therapeutics, Inc. 610 Main Street, 3Rd Floor Cambridge MA 02139		Yes	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2018-10-23	2,997,760	$0.00	2,997,760	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2018-10-23	490,000	$10.00	3,487,760	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2018-10-23	2,678,571	$0.00	1,402,444	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2018-10-23	3,046,943	$0.00	1,595,316	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0			No	4	C	Indirect
0			No	4	C	Indirect

Footnotes

The total represents shares received upon conversion of Series A and Series B Convertible Preferred Stock.
Upon closing of the Issuer's initial public offering, each share of Series A and Series B Convertible Preferred Stock automatically converted into 0.5235794 shares of Common Stock without payment or further consideration. There was no expiration date for the Series A or Series B Convertible Preferred Stock.
The Reporting Person is an employee of OrbiMed Advisors Israel II Limited ("OrbiMed Limited"), which is the managing member of OrbiMed Israel GP II, L.P. ("OIP GP"). OIP GP is the general partner of OrbiMed Israel Partners II, L.P. ("OIP II"), the direct beneficial owner of these securities. By virtue of such relationships, OIP GP and OrbiMed Limited may be deemed to have voting and investment power over the securities held by OIP II. The Reporting Person disclaims beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of these securities in which the Reporting Person has no pecuniary interest.